Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Participants currently using estrogen-containing contraception, compared with non-users, also tended to have higher median 25(OH)D concentrations as well as lower frequency of anemia (hemoglobin <12 g/dl) and ever use of DMPA in the past.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

We conducted a cross-sectional analysis using enrollment data from the Study of Environment, Lifestyle & Fibroids (SELF), a cohort of 1693 Black women ages 23 to 35 years enrolled in years 2010 to 2012.

Source: Abstract.

As the SELF data were de-identified at Michigan State University, the conduct of research for the present study was deemed not to involve human subjects by the Human Research Protections Program (institutional review board).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Estrogen-containing contraceptive use and blood lead concentrations in a cohort of premenopausal individuals

Cross-sectional study · Environmental research · 2025

Original publication title

Estrogen-containing contraceptive use and blood lead concentrations in a cohort of premenopausal individuals

Lauren E. Chapman; Mandy S. Hall; Arianna Foster; Donna D. Baird; Quaker E. Harmon; Robert O. Wright; Julio A. Landero; Renee Heffron; Lauren A. Wise; Ganesa Wegienka; Ruth J. Geller; Amelia K. Wesselink; Samantha Schildroth; Janet E. Hall; Erik J. Tokar; Kristen Upson

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

After exposure, toxic metal lead is stored in the skeleton and is mobilized to systemic circulation with bone turnover. Given the bone-conserving properties of estrogen, we investigated whether current use of estrogen-containing contraception is associated with lower blood lead concentrations. We conducted a cross-sectional analysis using enrollment data from the Study of Environment, Lifestyle & Fibroids (SELF), a cohort of 1693 Black women ages 23 to 35 years enrolled in years 2010 to 2012. The study population was restricted to non-users of injectable hormonal contraception with questionnaire data on hormonal contraceptive use and laboratory data on whole blood lead concentrations (n = 1549).

The geometric mean blood lead concentrations for current users of estrogen-containing contraception and non-users were 0.41 μg/dl (95 % CI: 0.39 to 0.43) and 0.51 μg/dl (95 % CI: 0.50 to 0.52), respectively. After adjusting for age, education, current smoking status, alcohol consumption, recency of injectable contraceptive hormone use, and recent birth using a multivariable linear regression model to estimate the percent difference in blood lead concentrations, current use of estrogen-containing contraception was associated with an 11 % lower blood-lead concentrations (95 % CI: −16 %, −5 %).

In exploratory analyses considering contraceptive type, current combined oral contraceptive users (n = 187) had 10 % lower blood lead concentrations (95 % CI: −16 %, −4 %) and contraceptive vaginal ring/transdermal patch users (n = 33) had 18 % lower blood lead concentrations (95 % CI: −29 %, −5 %) compared with non-users. Given the known toxic effects of lead and the common use of estrogen-containing contraception, further research is warranted to confirm our observation of lower blood lead concentrations with current use of estrogen-containing contraception.

Authors’ abstract

After exposure, toxic metal lead is stored in the skeleton and is mobilized to systemic circulation with bone turnover. Given the bone-conserving properties of estrogen, we investigated whether current use of estrogen-containing contraception is associated with lower blood lead concentrations. We conducted a cross-sectional analysis using enrollment data from the Study of Environment, Lifestyle & Fibroids (SELF), a cohort of 1693 Black women ages 23 to 35 years enrolled in years 2010 to 2012. The study population was restricted to non-users of injectable hormonal contraception with questionnaire data on hormonal contraceptive use and laboratory data on whole blood lead concentrations (n = 1549).

The geometric mean blood lead concentrations for current users of estrogen-containing contraception and non-users were 0.41 μg/dl (95 % CI: 0.39 to 0.43) and 0.51 μg/dl (95 % CI: 0.50 to 0.52), respectively. After adjusting for age, education, current smoking status, alcohol consumption, recency of injectable contraceptive hormone use, and recent birth using a multivariable linear regression model to estimate the percent difference in blood lead concentrations, current use of estrogen-containing contraception was associated with an 11 % lower blood-lead concentrations (95 % CI: −16 %, −5 %).

In exploratory analyses considering contraceptive type, current combined oral contraceptive users (n = 187) had 10 % lower blood lead concentrations (95 % CI: −16 %, −4 %) and contraceptive vaginal ring/transdermal patch users (n = 33) had 18 % lower blood lead concentrations (95 % CI: −29 %, −5 %) compared with non-users. Given the known toxic effects of lead and the common use of estrogen-containing contraception, further research is warranted to confirm our observation of lower blood lead concentrations with current use of estrogen-containing contraception.

Publication and source details

Original title: Estrogen-containing contraceptive use and blood lead concentrations in a cohort of premenopausal individuals

Lauren E. Chapman; Mandy S. Hall; Arianna Foster; Donna D. Baird; Quaker E. Harmon; Robert O. Wright; Julio A. Landero; Renee Heffron; Lauren A. Wise; Ganesa Wegienka; Ruth J. Geller; Amelia K. Wesselink; Samantha Schildroth; Janet E. Hall; Erik J. Tokar; Kristen Upson

Environmental research · 2025

* Corresponding author. upsonkri@msu.edu (K. Upson).https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T02:47:56.163728+00:00

DOI: 10.1016/j.envres.2025.122935 · PMC12900035